Get this report today!
Table of Contents
Across the globe, regulators continue to develop the approval pathways and guidance regarding biosimilars. In the US, the FDA is currently consulting with various stakeholders regarding details of the US biosimilars pathway. While in the EU, the EMA is furthering development of approval pathways for biosimilar monoclonal antibodies
Features and benefits
* Provides global biosimilar sales (2008–10), in addition to the status of biosimilar approval pathways across the globe.
* Insight into the key biosimilar regulatory developments in the US, EU and emerging markets
Since the US biosimilars pathway leaves many of the details for approval up to the FDA, the regulator has sought consultation, with discussion focusing on user fees, interchangeability, comparative studies and exclusivity, among other issues.
In Europe, the European Medicines Agency (EMA) has been seeking to develop further guidance for more technically challenging products such as monoclonal antibodies, while UK regulatory authorities have given their backing for the use of number of biosimilars in the national health services of England and Scotland.
The Brazilian government has also shown willingness to embrace biosimilars in an effort to reduce ever-increasing government healthcare expenditure. However, in contrast, a number of biosimilars have been removed from the substitution list in Norway, following a court ruling.
Your key questions answered
* Evaluate the evolving regulatory environment around the world, and how this impacts biosimilar market access and uptake.
* Gain insight into the strategies employed by payers and pharmaceutical companies in response to these changes in the regulatory environment.
Talk to Amrita
+1 718 303 2019
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
World demand to increase 6.4% annually through 2017 World enzyme demand is forecast to rise 6.4 percent per annum to $6.9 billion in 2017. Increasing per capita incomes in developing countries will help ...
Biosimilar Index answers your questions, such as... - There are 15 biosimilar and non-comparable biologic (NCB) versions of bevacizumab (Avastin; Roche) in clinical development; with the Biosimilar Index ...
Membrane technology is widely used in various development phases of pharmaceutical, biopharmaceutical and life sciences industries. Membrane technology includes membrane applications from laboratory drug ...
... As a cand to be used in a subunit vaccine against swine erysipelas (imada et al. 1999; Kitajima et al. 2000), Replacing the cellular vaccines in use. The production of recombinant antigenic proteins ...
... Konstantinov kb, yoshida t: dielectric measurement to monitor the growth and the physiological states of biological cells. bioprocess engineering 1994, 11:213 222. 40. Luli gw, strohl wr: comparison of growth ...
Reportlinker.com © Copyright 2014. All rights reserved.